Dear Sir/Madam,

Infections affecting the hand and upper limb are commonly managed by tertiary hand surgery units.[@bib0001] These can be broadly classified into either bone and joint infections or skin and soft tissue infections. Often, there is significant variation in clinical presentation and current available microbiological diagnostics can be of limited value.[@bib0001] This may result in delayed definitive treatment or inaccurate diagnosis that could prolong hospitalisation or, in the worst case scenario, produce a life or limb threatening situation.[@bib0001]

In addition to limb elevation, splinting, adequate surgical drainage, and/or, debridement, microbiological sampling with targeted antimicrobial therapy forms the mainstay of management for hand infections. Traditional microscopy and culture is the current gold standard microbiological diagnostic process, but often takes 48-72 hours before a specific pathogen and susceptibility profile are identified. This may result in adverse outcomes particularly in severe infective hand conditions such as flexor sheath tenosynovitis, fight bites or necrotizing fasciitis.

Real-time Multiplex polymerase chain reaction (mPCR) is an established microbiological diagnostic method that detects the presence of DNA from several different bacterial targets simultaneously. Within a matter of hours this technology is able to detect organisms and in some instances provide evidence of antimicrobial resistance genes. mPCR has demonstrated benefits in diagnosis and treatment time compared to traditional culture based methods in a range of applications, including respiratory infections, bacteraemia in sepsis, and prosthetic joint infections.[@bib0002], [@bib0003], [@bib0004] However, mPCR does present higher costs compared with standard culture.

Presently, there is no published literature concerning the use of mPCR technology in the management of hand and upper limb infections. The potential benefits are clear although formal cost-analysis ought to be undertaken. Earlier identification of causative organisms in these cases is likely to result in less visits to the operating theatre for repeated washouts and reduced length of inpatient stay. This may offset the additional costs associated with this technology from a whole healthcare perspective. Following the coronavirus pandemic, many institutions may have molecular platforms able to be repurposed to wider infection diagnostics. As clinical teams have more ready access to mPCR, hand surgery teams should leverage this opportunity to utilise rapid diagnostics when managing severe hand infections.
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